Novartis cholesterol drug trial failure triggers selloff
By The BriefBrief
Novartis’s failed trial of a cholesterol drug aimed at lowering Lp(a) contributed to a broad selloff in biopharma stocks, alongside other drugmakers.
WHO:Novartis
WHAT:Novartis’s cholesterol drug trial failed, contributing to a broad selloff in biopharma stocks.
WHEN:Reported Sep 8, 2026 at 10:37 AM ET
WHERE:Location not specified
WHY:The selloff followed the failed trial results for a cholesterol drug targeting Lp(a), undermining the drugmakers’ Lp(a)-reduction strategy tied to cardiovascular risk.
Reporting from 2 identified publishers across this event arc.
